莫德纳mRNA流感疫苗获FDA受理，计划2026年流感季使用

Core Viewpoint - Moderna's mRNA-based flu vaccine application has been accepted by the FDA, with a review deadline set for August 1, 2026, after initial rejection due to clinical trial design issues [1] Group 1: FDA Review Process - The FDA initially rejected Moderna's application on February 10, 2026, citing flaws in clinical trial design [1] - Following further communication, the FDA reversed its decision and agreed to initiate the review process [1] Group 2: Regulatory Pathways - Moderna has proposed a regulatory pathway segmented by age groups: seeking standard approval for individuals aged 50 to 64 and accelerated approval for those aged 65 and older [1] - The company has committed to conducting additional studies in the elderly population post-approval [1] Group 3: Market Implications - If approved, the vaccine is expected to be available for the elderly population during the later part of the 2026 flu season [1]